Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 25, No 32 (November 10), 2007: pp. 5141
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.14.5649

This Article
Right arrow Full Text (PDF)
Right arrow Meetings Abstract Link
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

ERRATUM

In the June 20, 2007, supplement, the abstract by Papadimitrakopoulou et al entitled, "A phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I)" (J Clin Oncol 25:7589, 2007) contained errors.

In the Author Affiliations section, the location of the VU Medisch Centrum should have been given as Amsterdam, the Netherlands, and the location of the Universitatsklinikum, should have been given as Cologne, Germany.

In the Methods section, the first sentence was given as:

"Advanced NSCLC pts with adequate organ function, performance status = 2, failing either = 2 C (arm 1) or = 2 C and an EGFR-I (arm 2) were treated with R at 10 mg qd if tolerable until progression (PD)."

While it should have read:

"Advanced NSCLC pts with adequate organ function, performance status ≤ 2, failing either ≤ 2 C (arm 1) or ≤ 2 C and an EGFR-I (arm 2) were treated with R at 10 mg qd if tolerable until progression (PD)."

In the Results section, the second sentence was given as:

Demographics and patient disposition were (arm 1/arm 2): 42/43 (6 pts ongoing), female 38.1%/51.2%, never smoker 14.3%/44.2%, adenoca. 57.1%/62.8%, squamous cell ca. 21.4%/14.0%, BAC 2.4%/16.3%, others 19.1%/6.9%.

While it should have read:

Demographics and patient disposition were (arm 1/arm 2): 42/43 (7 pts ongoing), female 38.1%/51.2%, never smoker 14.3%/44.2%, adenoca. 57.1%/62.8%, squamous cell ca. 21.4%/14.0%, BAC 2.4%/16.3%, others 19.1%/6.9%.

Also in the Results section, the fourth to last sentence was given as:

"Best overall tumor response (arm 1/2 in %): confirmed PR (5.3/2.8), SD (44.7/44.4); SD = 12 weeks (34.2/41.7), duration of SD in days arm 1 (58 –267) and arm 2 (68 –231)."

While it should have read:

"Best overall tumor response (arm 1/2 in %): confirmed PR (5.3/2.8), SD (44.7/44.4); SD ≥ 12 weeks (34.2/41.7), duration of SD in days arm 1 (58 –267) and arm 2 (68 –231)."

The online version has been corrected in departure from the print.





This Article
Right arrow Full Text (PDF)
Right arrow Meetings Abstract Link
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online